In recent years, numerous studies have documented the importance of nano-based drug delivery systems for the successful treatment of diseases. One of the most promising vehicles are lipid nanoparticles (LNPs), which can be synthesized and scaled relatively easy as the COVID-19 pandemic has shown for the delivery of the mRNA vaccines. To assure greater patient access to LNP formulations the Myerson group focuses on the development and characterization of continuous LNP formation technologies to capture the benefits of integrated and continuous processing, including quality, speed to clinic, cost, flexibility, and security of production.